Premium
Factors associated with a second deferral among donors eligible for re‐entry after a false‐positive screening test for syphilis, HCV , HBV and HIV
Author(s) -
Grégoire Y.,
Germain M.,
Delage G.
Publication year - 2018
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12644
Subject(s) - deferral , medicine , syphilis , human immunodeficiency virus (hiv) , immunology , business , accounting
Background and Objectives Since 25 May 2010, all donors at our blood centre who tested false‐positive for HIV , HBV , HCV or syphilis are eligible for re‐entry after further testing. Donors who have a second false‐positive screening test, either during qualification for or after re‐entry, are deferred for life. This study reports on factors associated with the occurrence of such deferrals. Materials and Methods Rates of second false‐positive results were compared by year of deferral, transmissible disease marker, gender, age, donor status (new or repeat) and testing platform (same or different) both at qualification for re‐entry and afterwards. Chi‐square tests were used to compare proportions. Cox regression was used for multivariate analyses. Results Participation rates in the re‐entry programme were 42·1%: 25·6% failed to qualify for re‐entry [different platform: 2·7%; same platform: 42·9% ( P < 0·0001)]. After re‐entry, rates of deferral for second false‐positive results were 8·4% after 3 years [different platform: 1·8%; same platform: 21·4% ( P < 0·0001)]. Deferral rates were higher for HIV and HCV than for HBV at qualification when tested on the same platform. The risk, when analysed by multivariate analyses, of a second deferral for a false‐positive result, both at qualification and 3 years after re‐entry, was lower for donors deferred on a different platform; this risk was higher for HIV , HCV and syphilis than for HBV and for new donors if tested on the same platform. Conclusion Re‐entry is more often successful when donors are tested on a testing platform different from the one on which they obtained their first false‐positive result.